Companies working alongside providers to develop solutions to
serious public health needs
Merck (NYSE:MRK), known as MSD outside the United States and
Canada, and Premier Inc. (NASDAQ: PINC), a leading healthcare
improvement company, have agreed to collaborate on the
co-development of solutions to help improve population health.
Initially, the companies will focus on reducing fracture rates for
at-risk osteoporosis patients.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160630005626/en/
The collaboration agreement combines expertise and assets from
Merck, Premier’s performance improvement framework and analytics,
Premier’s alliance of health systems, and other healthcare leaders
to jointly develop and test effective solutions to help improve
patient care and wellness, and lower healthcare spending.
“This strategic collaboration presents a tremendous opportunity
to create solutions that accelerate change in an industry that is
addressing preventative care through new patient-centric quality
improvement and alternative payment models,” said Michael J.
Alkire, COO of Premier. “Together, Premier and Merck will work
alongside providers to develop and assess solutions that promote
wellness and better care for specific groups of at-risk patients
across the continuum, a central goal for all healthcare
stakeholders. We are excited to begin this work and look forward to
identifying opportunities to apply the insights gleaned from these
initiatives.”
Goal to improve care for osteoporosis patients
There are approximately 10 million Americans with osteoporosis,
of which about 80 percent are women. People with osteoporosis are
at an increased risk of fractures that may impact the quality of
life and may lead to hospitalization. In fact, it is estimated that
osteoporosis is responsible for two million broken bones and $19
billion in U.S. healthcare costs each year. Despite these
consequences, published data suggests that a substantial number of
diagnosed patients are not being treated for osteoporosis.
Merck and Premier will work with the National Osteoporosis
Foundation to co-develop and test performance improvement
solutions, including educational initiatives that are designed to
help improve the quality of care for diagnosed untreated patients
at risk of osteoporotic fracture. By finding ways to better
identify, assess and treat these patients at risk for fractures,
this collaboration seeks to reduce the incidence and burden of
osteoporotic fractures for both patients and society.
As part of the project, the organizations will work to identify
a core set of metrics for osteoporosis care and fracture prevention
that align with measures endorsed by the National Quality Forum, as
well as other quality measures such as Physician Quality Reporting
System measures. The collaboration will integrate Premier’s CECity
quality improvement analytics platform, the measure set, as well as
interventions for improvement such as virtual collaboration
community tools and performance reports, into a cloud-based
application to be automated and tested within volunteer Premier
member health systems.
“Our organizations are coming together in a unique way through
these initiatives, working to address serious healthcare
challenges,” said Dr. Julie Gerberding, executive vice president,
strategic communications, global public policy and population
health at Merck. “Together, Merck and Premier have the knowledge,
clinical data, experience and commitment to make a real difference
in population health management and bring value to our overall
healthcare system.”
Merck and Premier are currently exploring additional population
health improvement projects, including an initiative to increase
appropriate adult vaccination rates.
The financial terms of the agreements were not disclosed.
About Merck
For 125 years, Merck has been a global healthcare leader working
to help the world be well. Merck is known as MSD outside the United
States and Canada. Through its prescription medicines, vaccines,
biologic therapies, and animal health products, Merck works with
customers and operates in more than 140 countries to deliver
innovative health solutions. Merck also demonstrates its commitment
to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit
www.merck.com, as well as Twitter, Facebook, YouTube and
LinkedIn.
About Premier Inc.
Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement
company, uniting an alliance of approximately 3,600 U.S. hospitals
and 120,000 other providers to transform healthcare. With
integrated data and analytics, collaboratives, supply chain
solutions, and advisory and other services, Premier enables better
care and outcomes at a lower cost. Premier, a Malcolm Baldrige
National Quality Award recipient, plays a critical role in the
rapidly evolving healthcare industry, collaborating with members to
co-develop long-term innovations that reinvent and improve the way
care is delivered to patients nationwide. Headquartered in
Charlotte, N.C., Premier is passionate about transforming American
healthcare. Please visit Premier’s news and investor sites on
www.premierinc.com; as well as Twitter, Facebook, LinkedIn,
YouTube, Instagram and Premier’s blog for more information about
the company.
Forward-looking statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the companies’ patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2015
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
Forward-looking statements of Premier Inc.
Matters discussed in this release that are not statements of
historical or current facts, as discussed herein, are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements may involve known and unknown risks, uncertainties and
other factors that may cause the actual results, performance or
achievements of Premier to be materially different from historical
results or from any future results or projections expressed or
implied by such forward-looking statements. Accordingly, readers
should not place undue reliance on any forward looking statements.
In addition to statements that explicitly describe such risks and
uncertainties, readers are urged to consider statements in the
conditional or future tenses or that include terms such as
“believes,” “belief,” “expects,” “estimates,” “intends,”
“anticipates” or “plans” to be uncertain and forward-looking.
Forward-looking statements may include comments as to Premier’s
beliefs and expectations as to future events and trends affecting
its business and are necessarily subject to uncertainties, many of
which are outside Premier’s control. More information on potential
factors that could affect Premier’s financial results is included
from time to time in the “Forward Looking Statements,” “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” sections of Premier’s periodic
and current filings with the SEC and available on Premier’s website
at investors.premierinc.com. Forward looking statements speak only
as of the date they are made. Premier undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise that
occur after that date.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160630005626/en/
- Morgan Guthrie, Public Relations, Premier Inc.;
Morgan_Guthrie@PremierInc.com; 704-816-4152- Patrick Witmer, Global
Communications, Merck; Patrick_Witmer@Merck.com; 267-305-4910-
Pamela Eisele, Media Relations, Merck; Pamela_Eisele@Merck.com;
267-305-3558- Teri Loxam, Investor Relations, Merck;
Teri.Loxam@Merck.com; 908-740-1986- Justin Holko, Investor
Relations, Merck; Justin_Holko@Merck.com; 908-740-1879- Claire
Gill, Consumer and Corporate Outreach, National Osteoporosis
Foundation; Claire.gill@nof.org; 703-647-3025
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024